In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo, and the lipid improvements tracked closely with this weight reduction 1
emerging evidence suggests they may offer psychiatric benefits: reduced binge-eating impulses, decreased substance cravings, and potentially improved mood independent of weight loss
They prioritize a high-protein, high-fiber diet to preserve muscle mass, which helps reduce body fat and prevent weight gain
GLP-1 works best as support for healthier eating and regular movement, not as a replacement
And direct GLP-1 receptor activation in neurons appears to modulate microglial activity, dampening the chronic immune response that underlies much late-life cognitive decline
A cash-pay model means patients pay you directly no insurance billing, no prior auths, no claim denials